Physiologic Growth Hormone Effects in HIV Lipodystrophy

Inclusion Criteria: * Men and women age 18-60 * Previously diagnosed HIV infection * Stable antiviral regimen for at least 12 weeks prior to enrollment * Waist-to-hip ratio \>0.90 for men and \>0.85 for women * Evidence of at least one of the following recent changes: \*increased abdominal girth, \*relative loss of fat in the extremities, \*relative loss of fat in the face * Simulated peak GH response to arginine/GHRH of less than 7.5 mcg/dL Exclusion Criteria: * Use of Megace, anti-diabetic agents, GH, or other anabolic agents, pharmacologic glucocorticoid (prednisone \>5 mg/day or its equivalent) for 3 months prior to enrollment. Patients on a standard dose of testosterone for documented hypogonadism will be allowed to enter the protocol. Women taking standard estrogen replacement therapy for \>3 months will be allowed in the study. * Diabetes mellitus * Other severe chronic illness * HgB \<9.0 g/dL, creatinine \>1.4 mg/dL, or PSA \>4 ng/mL * Positive BHCG or failure to use appropriate birth control during study. Acceptable methods include oral contraceptives, depo provera or combined progesterone-estrogen injections, transdermal contraceptive patches, IUD's, barrier devices (condoms, diaphragms), and abstinence. * Carpal tunnel syndrome * Active malignancy or history of pituitary malignancy, history of colon cancer or prostate malignancy